Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular
Overview of cancer health disparities: Current state and future directions
Overview of cancer health disparities: Current state and future directions
Dr Ophira Ginsburg - National Cancer Institute, Bethesda, USA
Defining the role of immunotherapy in B-cell ALL
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
Defining the role of immunotherapy in B-cell ALL ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )
23 Jan 2020
Long-term toxicities in paediatric ALL
Prof Kjeld Schmiegelow - University of Copenhagen, Copenhagen, Denmark
Long-term toxicities in paediatric ALL ( Prof Kjeld Schmiegelow - University of Copenhagen, Copenhagen, Denmark )
23 Jan 2020
How is minimal residual disease managed in patients with ALL?
Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy
How is minimal residual disease managed in patients with ALL? ( Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy )
23 Jan 2020
BLAST: Blinatumomab for minimal residual disease in patients with ALL
Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy
BLAST: Blinatumomab for minimal residual disease in patients with ALL ( Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy )
23 Jan 2020
Frontline therapy of ALL
Prof Hervé Dombret - University Paris Diderot, Paris, France
Frontline therapy of ALL ( Prof Hervé Dombret - University Paris Diderot, Paris, France )
23 Jan 2020
BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL
Prof Hervé Dombret - University Paris Diderot, Paris, France
BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL ( Prof Hervé Dombret - University Paris Diderot, Paris, France )
23 Jan 2020
Treatment of Ph-negative ALL in adolescents and young adults
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
Treatment of Ph-negative ALL in adolescents and young adults ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jan 2020
The new era of ALL treatment
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
The new era of ALL treatment ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jan 2020
Safety considerations for inotuzumab in patients with relapsed/refractory ALL
Prof David Marks - University Hospitals Bristol NHS Foundation Trust, Bristol...
Safety considerations for inotuzumab in patients with relapsed/refractory ALL ( Prof David Marks - University Hospitals Bristol NHS Foundation Trust, Bristol, UK )
23 Jan 2020
HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2...
Dr Rashmi Murthy - MD Anderson Cancer Center, Houston, USA
HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-positive metastatic breast cancer ( Dr Rashmi Murthy - MD Anderson Cancer Center, Houston, USA )
23 Jan 2020
Oral paclitaxel yields better outcomes than IV paclitaxel in metastatic breast...
Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras
Oral paclitaxel yields better outcomes than IV paclitaxel in metastatic breast cancer ( Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras )
23 Jan 2020
Novel therapeutic approaches in B-progenitor ALL
Dr Charles Mullighan - St. Jude's Children's Research Hospital, Memphis, USA
Novel therapeutic approaches in B-progenitor ALL ( Dr Charles Mullighan - St. Jude's Children's Research Hospital, Memphis, USA )
23 Jan 2020

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation